Maxim Group
http://www.maximgrp.com/Maxim Group is a financial services firm that provides investment banking, asset management, research, and sales & trading to a diverse range of corporate clients, institutional investors and high net worth individuals.
The firm’s research division uses fundamental research and a “bottom up” approach to making investment recommendations. Maxim’s research analysts focus on under-covered, small- to mid-cap names in a variety of sectors including healthcare, technology, retail and others.
View Older Stories View More Recent Stories
-
Aftermaster Partners With Maxim Group LLC For Investment Banking Services
-
Maxim Group Reiterates Buy Rating and $4 PT on CASI Pharmaceuticals (CASI); Patient Enrollment for Ph2 ENMD-2076 Study is Complete
-
Maxim Group Maintains Buy Rating and $6 PT on Intellipharmaceutics (IPCI) Following 1Q Results Miss; 'Focused on Rexista Now'
-
Maxim Group Reiterates Buy Rating and $21 PT on Sucampo Pharmaceuticals (SCMP); 'We See Upside in the Stock'
-
Maxim Group Upgrades TrovaGene (TROV) to Buy
-
TICC Capital Corp. Completes Public Offering of $64,370,225 6.50% Notes Due 2024
-
Virtual Health Partners Closes Series A Financing
-
PlacementTracker Publishes Q1 2017 Private Placement Market League Tables
-
Cytori Therapeutics (CYTX) Prices 8.6M Common Stock Offering at $1.10/Share
-
Cytori Announces Pricing of $9.5M Public Offering of Common Stock
-
OneSoft Subsidiary, OneBridge Solutions Inc., Presents at Banff 2017 Pipeline Workshop; OneSoft Presents at Microcap Investors Conference in New York City
-
Naked Brand (NAKD) Raises $5.5M from ATM Program; Amends LOI with Bendon
-
Naked Brand Group Announces $5.5 Million in Gross Proceeds from Completed At The Market Offering; Amends LOI with Bendon to Reflect $34 Million in Expected Balance Sheet Improvements
-
Cytori Therapeutics (CYTX) to Offer Common Stock via Maxim Group
-
Cytori Announces Proposed Public Offering of Common Stock
-
Maxim Group Reiterates Buy Rating and $14 PT on Abeona Therapeutics (ABEO) Ahead of ABO-102 Incremental Data Presentation on 4/11
-
Maxim Group Reiterates Buy Rating and $6 PT on Intellipharmceutics (IPCI) Following Lawsuit from Purdue Pharma Over Rexista
-
Maxim Group Reiterates Buy Rating and $14 PT on Mesoblast Limited (MESO); 'Successful Interim Analysis of Efficacy Endpoint in Pivotal Heart Failure Trial'
-
Maxim Group Downgrades Fifth Street Senior (FSFR) to Hold
-
BioLineRx Closes $28.75 Million Underwritten Public Offering of its American Depositary Shares
-
TICC Capital Corp. Prices Public Offering of $57.5 Million 6.50% Notes Due 2024
-
New Age Beverages Corporation Announces Investor Conference Call to Discuss 2016 Results
-
Versus Systems to Present at the MicroCap Conference in New York City at the Essex House
-
TICC Capital Corp. Announces Offering of Notes
-
Seanergy Maritime Holdings Corp. Reports Financial Results for the Fourth Quarter and Twelve Months Ended December 31, 2016
-
Sucampo Pharmaceuticals (SCMP) PT Raised to $21 at Maxim Group; Vtesse 'Could Be a Great Deal'
-
Kite Pharma (KITE) PT Raised to $100 at Maxim Group
-
First Capital Real Estate Trust Incorporated And PhotoMedex, Inc. Announce Entry Into Contribution Agreement
-
BioLineRx (BLRX) Prices 29.4M Offering at $0.85/ADS
-
BioLineRx Prices $25 Million Underwritten Public Offering
-
Cytosorbents (CTSO) Prices 2.22M Share Follow-On Offering at $4.50
-
CytoSorbents Announces Pricing of Follow-On Offering
-
Maxim Group Reiterates Buy Rating and $14 PT on Mesoblast Limited (MESO); 'Locking the Database Up for Interim Analysis'
-
Maxim Group Upgrades Vertex (VRTX) to Buy
-
Maxim Group Reiterates Buy Rating and $11 PT on Intec Phara (NTEC); 'Ph3 Accordian Study Unfolding as Planned'
-
Maxim Group Reiterates Buy Rating and $22 PT on Omeros (OMER) Following Positive OMS721 Phase 2 Trial Data
-
Maxim Group Reiterates Buy Rating and $11 PT on AEterna Zentaris (AEZS) Following News of Macrilen NDA in 3Q17
-
Brainstorm Cell Therapeutics (BCLI) PT Raised to $8 at Maxim Group
-
Maxim Group Downgrades Ritter Pharmaceuticals (RTTR) to Hold
-
Maxim Group Reiterates Buy Rating and $22 PT on Omeros (OMER) Following OMS721 Positive Case Report
-
First Choice Healthcare Solutions to Present at the Microcap Conference on April 4, 2017 in New York City
-
Maxim Group Reiterates Buy and $32 PT on Zynerba Pharma (ZYNE) Following 4Q Results; 'P2 POC Data in Epilepsy Approaching in 3Q17'
-
Maxim Group Starts VistaGen Therapeutics (VTGN) at Buy
-
Maxim Group Reiterates Hold Rating on NovaBay Pharma (NBY) Following 4Q Results
-
Maxim Group Maintain Buy Rating and $9 PT on Galmed Pharma (GLMD) Following Q4 EPS Miss; 'Lack of N-T Catalysts'
-
Maxim Group Reiterates Buy Rating and $9 PT on Intec Pharma (NTEC) Following Ph1 Trial Initiation of CBD/THC Using the Accordion Delivery System
-
Interpace Diagnostics (IDXG) Enters Agreement to Restructure Debt and Terminate Royalty and Milestone Obligations
-
Interpace Diagnostics Group Announces Agreements to Successfully Restructure Debt and Terminate Royalty and Milestone Obligations
-
Maxim Group Downgrades Nimble Storage (NMBL) to Hold Following Deal With Hewlett Packard Enterprise (HPE)
-
Maxim Group Reiterates Buy Rating and $10 PT on Cytosorbents (CTSO) Following Dr. Carl June's Election to the Advisory Board

